Treatment type
Treatments and trials using Infusion, with the same country and access zoom as New Developments.
All New Developments
Isembyld (apitegromab-mstn) — a once-every-4-weeks IV medicine that targets muscle for people with SMA already on an SMN2 treatment
FDA approval on 11 September 2026 for Isembyld (apitegromab-mstn) injection — a muscle-targeted intravenous medicine — for spinal muscular…
This is for children and adults living with SMA who are already on an SMN2-targeted treatment (such as…
Revtorpyk (gedatolisib) — IV pan-PI3K/mTOR inhibitor for HR+/HER2−, PIK3CA-wild-type advanced breast cancer
On 14 July 2026 the FDA labelled Revtorpyk (gedatolisib) for injection — an intravenous kinase inhibitor of class I PI3K isoforms (α, β, δ, γ)…
Revtorpyk is a US-labelled IV pan-PI3K / mTOR inhibitor used with fulvestrant, with or without…
Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP)
The FDA labelled an intravenous activin A–blocking monoclonal antibody on 19 August 2026 to reduce formation of new heterotopic ossification (HO)…
The FDA labelled an intravenous activin A–blocking monoclonal antibody on 19 August 2026 to reduce…
Lumvoa (veligrotug-vvze) for thyroid eye disease (active and chronic)
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease activity or duration on 26 June 2026. The…
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease…